Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
IMUNON, Inc. (Nasdaq: IMNN) Just Landed On Paul Prescott's Watchlist This Morning—Thursday, July 30, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get IMNN On Your Radar While It’s Still Early… July 30, 2026 Dear Reader, If you missed our first update last night, here is the setup on IMUNON, Inc. (Nasdaq: IMNN) you need before the bell rings. Street Ideas is always looking for late-stage clinical companies where the story behind the setup looks like it could accelerate, and IMNN is one of them right now. Two positive clinical readouts in just three days is the kind of momentum most late-stage clinical companies do not produce in an entire quarter. IMNN delivered exactly that between July 21 and July 23, and it is hosting its Q2 2026 earnings call next Tuesday, August 4, 2026 at 11:00 a.m. EDT. That is three events inside a two-week window, which is a potential catalyst cluster worth keeping an eye on. What makes it stand out from the Street Ideas desk is the fact that IMNN also carries a tight share structure, an FDA-aligned Phase 3 protocol, and a confirmed path toward a Biologics License Application filing. The clinical readouts themselves reinforce the setup. On July 21, IMNN reported fresh preliminary data from its Phase 2 residual disease trial led by researchers at MD Anderson in partnership with Break Through Cancer. Two days later, on July 23, IMNN was invited to present additional clinical data at the inaugural AACR D3 conference in Boston. Both readouts landed inside the same week, and both fit the same narrative management has been building toward the Phase 3 primary analysis. These are only some of the reasons IMNN is topping the Street Ideas watchlist this morning, Thursday, July 30, 2026. 
But keep in mind, IMNN has less than 4M shares listed as available to the public right now. When companies have small public floats like this, the potential exists for big moves. Analyst coverage adds another layer to the story. IMNN has a Strong Bullish consensus with an average 12-month target of $17.00, while published targets include $12 from Alliance Global Partners, $10 from Maxim Group, $25 from H.C. Wainwright, and a $25 valuation from Zacks Research. With clinical data continuing to strengthen the case and several key milestones now converging, IMNN could be entering one of the most important stretches in its recent history. Before we break down each of those developments, it is worth taking a closer look at the company and the science driving its lead program. Inside (IMNN)'s Late-Stage Clinical Program
IMUNON is a clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey, developing DNA-based therapies for cancer and infectious disease. The lead program, IMNN-001, is a DNA-based therapy that instructs the body to produce a protein called IL-12 locally at the tumor site, activating the immune cells that hunt down cancer. IMNN-001 is delivered directly into the abdominal cavity once a week over a six-month course. 
That local, sustained approach is designed specifically to unlock IL-12's cancer-fighting potential without the toxicity that limited earlier attempts. The Company runs two platforms. TheraPlas supports the lead oncology program, while PlaCCine is a DNA-based vaccine platform that produced IMNN-101, tested as a COVID-19 booster candidate in a first-in-human study. Stacy Lindborg, Ph.D. leads the executive team as President and Chief Executive Officer, with Douglas V. Faller, M.D., Ph.D. serving as Chief Medical Officer and Josh Blacher serving as interim Chief Financial Officer. IMNN-001 has completed six ovarian cancer clinical trials to date and is now enrolling in the Phase 3 OVATION 3 registrational trial. The Broader Market Story Behind IMNN Street Ideas looks closely at the sector backdrop behind every late-stage clinical name we cover, and IMNN sits in one of the fastest-growing corners of healthcare. According to Precedence Research, the global cancer immunotherapy market sits at $136.39B in 2025, is projected to grow to $151.26B in 2026, and is expected to reach $367.63B by 2035 at a 10.42% compound annual growth rate. 
North America leads with a 42.14% revenue share, and hospitals continue to be the primary channel for immunotherapy delivery. Additional sizing from Grand View Research and Research and Markets point to the same directional story, with the tighter immuno-oncology therapeutics segment projected to reach $226.31B by 2030. That is the kind of tailwind Street Ideas wants behind a late-stage clinical program. Ovarian cancer, the target indication for IMNN-001, remains one of the most challenging gynecologic cancers to treat. More than 60% of women diagnosed die within five years, and most cases are not detected until the disease has already spread. Approximately 20,000 new cases are diagnosed in the U.S. each year and roughly 300,000 worldwide. The frontline standard of care has not seen a real advance in more than three decades. That is the gap IMNN-001 is being positioned to close as a first-in-class local immunotherapy with no direct competitor in the frontline setting, and it is the reason IMNN keeps landing on the Street Ideas radar. What Put IMNN On Our Radar
Potential Catalyst Calendar That Keeps Building. July 21 residual disease readout, July 23 AACR D3 selection, and Q2 2026 earnings on August 4. Three events inside two weeks is unusual for a late-stage clinical name. Fresh Phase 2 Residual Disease Readout. The July 21, 2026 update from the MD Anderson-led trial showed less residual disease at follow-up surgery (44% versus 67%), better tumor DNA clearance (87.5% versus 62.5%), and 100% no evidence of disease versus 56% in the control arm. AACR D3 Selection. Two days later, IMNN-001 was showcased at the inaugural AACR D3 conference in Boston with a favorable immune-cell response and clean safety profile. Landmark Survival Data Behind It. The final March 25, 2026 Phase 2 OVATION 2 readout showed a 14.7-month median overall survival benefit, extending to 24.2 months with targeted maintenance therapy. Phase 3 Enrollment Ahead Of Plan. The June 23, 2026 iDMC vote confirmed the Phase 3 OVATION 3 study should continue without modification, with 27 of 80 target patients already dosed for Q1 2027. Published Analyst Targets Point Higher. IMNN carries a Strong Bullish analyst consensus with an average 12-month target of $17.00, a significant premium to recent share levels. Recent Milestones Behind IMNN
July 23, 2026: IMNN-001 featured in poster at inaugural AACR D3 conference in Boston July 21, 2026: Fresh positive Phase 2 residual disease data reported from MD Anderson-led trial June 23, 2026: Independent DMC recommended Phase 3 OVATION 3 continue without modification June 4, 2026: Up to $10M cash financing announced, structured without warrants May 12, 2026: Q1 2026 results confirmed FDA alignment on Phase 3 protocol and BLA path March 25, 2026: Final Phase 2 OVATION 2 data showed 14.7-month median overall survival benefit July 30, 2025: First patient dosed in the Phase 3 OVATION 3 study Why IMNN Is Topping This Morning’s Watchlist
—Thursday, July 30, 2026…
1. Analyst Coverage: Published coverage gives IMNN a Strong Bullish consensus and an average 12-month target of $17.00, with individual figures ranging from $10 to $25.
2. Very Small Float: With fewer than 4M shares listed as available to the public, IMNN’s small float could have the potential for big moves if demand begins to change. 3. Clinical Momentum: Two positive clinical readouts within three days have placed IMNN in the spotlight ahead of its next scheduled corporate update. 4. Survival Data: Final Phase 2 results showed IMNN-001 delivered a 14.7-month median overall survival benefit, rising to 24.2 months among women also receiving targeted maintenance therapy. 5. Phase 3 Progress: After an independent committee recommended continuing the study without modification, IMNN remained on track to reach 80 enrolled participants by Q1 2027. 6. Residual Disease: Fresh Phase 2 findings showed the IMNN-001 group had less residual disease, stronger tumor-DNA clearance, and a higher no-evidence-of-disease rate than the control arm. 7. FDA Pathway: With its Phase 3 protocol developed in agreement with the FDA and a confirmed path toward a Biologics License Application filing, IMNN has a defined regulatory framework for its lead program. Get IMNN On Your Radar While It’s Still Early…
At Street Ideas, we look for companies where multiple developments begin coming together over a relatively short period of time. IMNN now checks several of those boxes with fresh clinical data, an upcoming earnings call, a defined regulatory path, and published analyst targets ranging from $10 to $25. We'll continue monitoring the story closely. Be sure to take another look at IMNN while it’s still early, and keep an eye on your inbox for my next update. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter |
0 التعليقات:
إرسال تعليق